

## CONTACTS & KEY INFORMATION

**Headquarters:** 267 Boston Road  
Suite 28  
North Billerica, MA 01862  
978-474-9300

**Website:** www.hydrocision.com

**Sector:** Medical Device, Spine Sector

**Investors:** Triathlon Medical Ventures,  
Oxford Bioscience Partners,  
BioVentures Investors, LLC,  
Omega Fund, Box Equity

**Financing:** Privately Held; \$36.9M raised to date

## MANAGEMENT TEAM

**Douglas J. Daniels**

President and CEO

**Paul Kowalski**

Vice President, Sales & Marketing

**Kevin P. Staid**

Chief Technical Officer and  
Vice President, Application Development

**John C. Miller**

Chief Operating Officer

**James H. Hill**

Vice President, Quality, Regulatory and  
Clinical Affairs

**Patricia A. Van Blarcom**

Chief Financial Officer

## Board of Directors

**Lew Bennett**

President and CEO, Custom Spine Inc.

**Alastair J.T. Clemow**

President and CEO, Nexgen Spine Inc.

**Dennis B. Costello**

Managing Partner, Triathlon Medical Ventures

**Douglas J. Daniels**

President and CEO, HydroCision

**Jonathan Fleming**

Managing Partner, Oxford Bioscience Partners

**Marc Goldberg**

Managing Partner, BioVentures Investors, LLC

**Richard J. Lim**

Venture Partner, Omega Funds

## H I G H L I G H T S...


- ◆ **THE MARKET OPPORTUNITY FOR SPINEJET PRODUCTS** that provide less invasive alternatives to treating back pain with positive clinical and economic outcomes is large – approximately \$800 million in 2009 – and growing quickly – to approximately \$1.1 billion by 2014.
- ◆ **HYDROCISION HAS 46 ISSUED AND ALLOWED PATENTS WORLDWIDE** and another 38 patents pending that provide sustainable competitive advantages for its unique products which satisfy doctor, patient and payor needs. These patents provide significant barriers to entry for additional competitors entering into the field.
- ◆ **THE COMPANY'S SPINEJET PERCUTANEOUS, ENDOSCOPIC AND MICRODISCECTOMY SYSTEMS** represent major advances in minimally invasive discectomy procedures –harnessing the power of water-based technology for better clinical and economic outcomes.
- ◆ **THE COMPANY'S SPINEJET XL PRODUCTS** are clinically proven to optimize disc preparation improving patient outcomes while delivering, financial and operational solutions to hospitals and outpatient centers.
- ◆ **HYDROCISION HAS A SEASONED MEDICAL DEVICE MANAGEMENT TEAM** that has positioned the company for and achieved double digit growth in a variety of surgical applications. Currently these include open and minimally invasive spine surgery, wound debridement, and general surgery.
- ◆ **THE COMPANY HAS VALIDATED ITS TECHNOLOGY** in over forty thousand clinical procedures.
- ◆ **HYDROCISION IS WELL-POSITIONED** to optimize the value of its technology in additional clinical specialties including ENT, Plastic Surgery, OB/GYN, Urology, and General Surgery.

## SCIENTIFIC ADVISORY BOARD



**Mitchell A Hardenbrook, M.D.**

Assist Prof of Surgery,  
Uniformed Services  
University of Health  
Sciences, The Boston Spine  
Group



**Larry T. Khoo, M.D.**

Neurosurgeon  
The Spine Clinic of Los  
Angeles  
Los Angeles, CA



**Bryan Fox, M.D.**

Director of Spine Surgery  
Naval Hospital,  
Portsmouth, VA